vs
Side-by-side financial comparison of NextPlat Corp (NXPL) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
NextPlat Corp is the larger business by last-quarter revenue ($12.8M vs $9.3M, roughly 1.4× STRATA Skin Sciences, Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -40.2%, a 40.8% gap on every dollar of revenue. On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -21.1%). NextPlat Corp produced more free cash flow last quarter ($-339.0K vs $-551.0K). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -14.4%).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
NXPL vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.8M | $9.3M |
| Net Profit | $-5.1M | $58.0K |
| Gross Margin | 14.3% | 61.8% |
| Operating Margin | -28.9% | 5.3% |
| Net Margin | -40.2% | 0.6% |
| Revenue YoY | -21.1% | -3.0% |
| Net Profit YoY | -70.6% | 101.3% |
| EPS (diluted) | — | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.8M | $9.3M | ||
| Q3 25 | $13.8M | $6.9M | ||
| Q2 25 | $13.2M | $7.7M | ||
| Q1 25 | $14.5M | $6.8M | ||
| Q4 24 | $16.2M | $9.6M | ||
| Q3 24 | $15.4M | $8.8M | ||
| Q2 24 | $17.0M | $8.4M | ||
| Q1 24 | $17.5M | $6.8M |
| Q4 25 | $-5.1M | $58.0K | ||
| Q3 25 | $-2.2M | $-1.6M | ||
| Q2 25 | $-1.8M | $-2.6M | ||
| Q1 25 | $-1.3M | $-2.1M | ||
| Q4 24 | $-3.0M | $-4.6M | ||
| Q3 24 | $-4.2M | $-2.1M | ||
| Q2 24 | $-5.3M | $-91.0K | ||
| Q1 24 | $-1.5M | $-3.4M |
| Q4 25 | 14.3% | 61.8% | ||
| Q3 25 | 19.9% | 60.4% | ||
| Q2 25 | 21.8% | 56.2% | ||
| Q1 25 | 23.8% | 53.5% | ||
| Q4 24 | 16.8% | 61.4% | ||
| Q3 24 | 23.2% | 60.1% | ||
| Q2 24 | 34.5% | 59.0% | ||
| Q1 24 | 27.8% | 45.6% |
| Q4 25 | -28.9% | 5.3% | ||
| Q3 25 | -14.5% | -16.9% | ||
| Q2 25 | -13.8% | -30.1% | ||
| Q1 25 | -10.2% | -25.0% | ||
| Q4 24 | -14.1% | -44.7% | ||
| Q3 24 | -52.1% | -18.2% | ||
| Q2 24 | -64.1% | -5.7% | ||
| Q1 24 | -10.5% | -42.7% |
| Q4 25 | -40.2% | 0.6% | ||
| Q3 25 | -15.9% | -23.4% | ||
| Q2 25 | -13.5% | -33.6% | ||
| Q1 25 | -9.2% | -31.2% | ||
| Q4 24 | -18.6% | -47.6% | ||
| Q3 24 | -27.4% | -23.6% | ||
| Q2 24 | -31.3% | -1.1% | ||
| Q1 24 | -8.5% | -49.8% |
| Q4 25 | — | $0.14 | ||
| Q3 25 | — | $-0.36 | ||
| Q2 25 | — | $-0.62 | ||
| Q1 25 | $-0.05 | $-0.51 | ||
| Q4 24 | — | $-2.01 | ||
| Q3 24 | $-0.22 | $-0.51 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | $-0.08 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.7M | $7.9M |
| Total DebtLower is stronger | $1.3M | $15.3M |
| Stockholders' EquityBook value | $17.3M | $2.9M |
| Total Assets | $27.5M | $30.5M |
| Debt / EquityLower = less leverage | 0.07× | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.7M | $7.9M | ||
| Q3 25 | $13.9M | $7.1M | ||
| Q2 25 | $16.6M | $6.0M | ||
| Q1 25 | $17.7M | $6.5M | ||
| Q4 24 | $20.0M | $7.3M | ||
| Q3 24 | $20.4M | $7.1M | ||
| Q2 24 | $24.9M | $5.5M | ||
| Q1 24 | $23.5M | $5.2M |
| Q4 25 | $1.3M | $15.3M | ||
| Q3 25 | $1.2M | $15.3M | ||
| Q2 25 | $1.2M | $15.0M | ||
| Q1 25 | $1.3M | $15.0M | ||
| Q4 24 | $1.4M | $15.0M | ||
| Q3 24 | $1.5M | $15.0M | ||
| Q2 24 | $1.3M | $15.0M | ||
| Q1 24 | $1.4M | $15.0M |
| Q4 25 | $17.3M | $2.9M | ||
| Q3 25 | $21.4M | $1.3M | ||
| Q2 25 | $23.5M | $532.0K | ||
| Q1 25 | $25.3M | $3.0M | ||
| Q4 24 | $27.3M | $5.0M | ||
| Q3 24 | $22.5M | $9.4M | ||
| Q2 24 | $26.5M | $9.5M | ||
| Q1 24 | $31.2M | $9.4M |
| Q4 25 | $27.5M | $30.5M | ||
| Q3 25 | $30.0M | $30.7M | ||
| Q2 25 | $31.0M | $29.5M | ||
| Q1 25 | $35.2M | $33.0M | ||
| Q4 24 | $37.1M | $34.9M | ||
| Q3 24 | $41.1M | $39.4M | ||
| Q2 24 | $51.5M | $38.8M | ||
| Q1 24 | $65.1M | $39.2M |
| Q4 25 | 0.07× | 5.28× | ||
| Q3 25 | 0.05× | 11.65× | ||
| Q2 25 | 0.05× | 28.20× | ||
| Q1 25 | 0.05× | 5.04× | ||
| Q4 24 | 0.05× | 3.02× | ||
| Q3 24 | 0.07× | 1.60× | ||
| Q2 24 | 0.05× | 1.58× | ||
| Q1 24 | 0.04× | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-302.0K | $-239.0K |
| Free Cash FlowOCF − Capex | $-339.0K | $-551.0K |
| FCF MarginFCF / Revenue | -2.6% | -5.9% |
| Capex IntensityCapex / Revenue | 0.3% | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-302.0K | $-239.0K | ||
| Q3 25 | $-2.7M | $-64.0K | ||
| Q2 25 | $-1.0M | $-1.9M | ||
| Q1 25 | $-2.1M | $-550.0K | ||
| Q4 24 | $-476.0K | $703.0K | ||
| Q3 24 | $-4.6M | $-302.0K | ||
| Q2 24 | $2.3M | $591.0K | ||
| Q1 24 | $-2.7M | $-804.0K |
| Q4 25 | $-339.0K | $-551.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | $-1.1M | $-2.0M | ||
| Q1 25 | $-2.1M | $-749.0K | ||
| Q4 24 | $-508.0K | $199.0K | ||
| Q3 24 | $-4.7M | $-364.0K | ||
| Q2 24 | $2.2M | $246.0K | ||
| Q1 24 | $-2.7M | $-1.5M |
| Q4 25 | -2.6% | -5.9% | ||
| Q3 25 | — | -15.6% | ||
| Q2 25 | -8.0% | -26.1% | ||
| Q1 25 | -14.3% | -11.0% | ||
| Q4 24 | -3.1% | 2.1% | ||
| Q3 24 | -30.6% | -4.1% | ||
| Q2 24 | 13.2% | 2.9% | ||
| Q1 24 | -15.7% | -22.6% |
| Q4 25 | 0.3% | 3.4% | ||
| Q3 25 | 0.0% | 14.7% | ||
| Q2 25 | 0.1% | 0.8% | ||
| Q1 25 | 0.2% | 2.9% | ||
| Q4 24 | 0.2% | 5.3% | ||
| Q3 24 | 0.6% | 0.7% | ||
| Q2 24 | 0.4% | 4.1% | ||
| Q1 24 | 0.4% | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NXPL
| Healthcare Operations | $9.0M | 70% |
| Ecommerce Revenue | $3.8M | 30% |
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
